Ensysce Biosciences Inc.
Crafting carbon nanotubes to deliver RNA therapeutics
This article was originally published in Start Up
Executive Summary
Ensysce Biosciences Inc. is developing a nanoscaled delivery system that might work for many types of potential drugs but will first be applied to siRNAs, a class of drug candidates that inspired tremendous excitement a decade ago, but has since been abandoned by many of its former champions. The Houston, TX-based start-up believes it can harness single-walled carbon nanotubes to deliver siRNAs that will block or “silence” the genetic instructions encoded by messenger RNA, and thereby stop targeted genes from producing disease-related protein.
You may also be interested in...
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.